Drug profile · INN
repaglinide
REPAGLINIDE SUN
repaglinide (REPAGLINIDE SUN) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — repaglinide
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
repaglinide (REPAGLINIDE SUN) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sulfonylurea receptor 1, Kir6.2 blocker
Primary target: Sulfonylurea receptor 1, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is repaglinide?
repaglinide (REPAGLINIDE SUN) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for repaglinide?
REPAGLINIDE SUN is a marketed brand name for repaglinide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of repaglinide?
repaglinide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.